Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 7, 2011 - Issue 2
Submit an article Journal homepage
437
Views
7
CrossRef citations to date
0
Altmetric
Meeting Report

Heterogeneity versus homogeneity of multiple sclerosis

Fumitaka Sato Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA; Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
,
Nicholas E Martinez Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA; Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
,
Seiichi Omura Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA; Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
&
Ikuo Tsunoda Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA;[email protected]
Pages 165-167 | Published online: 10 Jan 2014

References

  • Lim SY, Constantinescu CS. Current and future disease-modifying therapies in multiple sclerosis. Int. J. Clin. Pract.64(5), 637–650 (2010).
  • Hartung H-P, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann. Neurol.66(4), 429–432 (2009).
  • Martin R. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis. Lancet Neurol.7(9), 765–766 (2008).
  • Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol.7(9), 796–804 (2008).
  • Hawker K, O’Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol.66(4), 460–471 (2009).
  • Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med.7(3), 115–121 (2001).
  • Raine CS. Multiple sclerosis: classification revisited reveals homogeneity and recapitulation. Ann. Neurol.63(1), 1–3 (2008).
  • Breij ECW, Brink BP, Veerhuis R et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol.63(1), 16–25 (2008).
  • Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol.55(4), 458–468 (2004).
  • Barnett MH, Parratt JD, Pollard JD, Prineas JW. MS: is it one disease? Int. MS J.16(2), 57–65 (2009).
  • Geurts JJG, Stys PK, Minagar A, Amor S, Zivadinov R. Gray matter pathology in (chronic) MS: modern views on an early observation. J. Neurol. Sci.282(1–2), 12–20 (2009).
  • Geurts JJG, Kooi E-J, Witte ME, van der Valk P. Multiple sclerosis as an ‘inside-out’ disease. Ann. Neurol.68(5), 767–768; author reply 768 (2010).
  • Nave K-A. Myelination and the trophic support of long axons. Nat. Rev. Neurosci.11(4), 275–283 (2010).
  • Nave K-A, Trapp BD. Axon–glial signaling and the glial support of axon function. Annu. Rev. Neurosci.31, 535–561 (2008).
  • Werner HB, Kuhlmann K, Shen S et al. Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J. Neurosci.27(29), 7717–7730 (2007).
  • Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science305(5686), 1010–1013 (2004).
  • Sato F, Tanaka H, Hasanovic F, Tsunoda I. Theiler’s virus infection: pathophysiology of demyelination and neurodegeneration. Pathophysiology18(1), 31–41 (2011).
  • Sato F, Omura S, Martinez NE, Tsunoda I. Animal models of multiple sclerosis. In: Neuroinflammation. Minagar A (Ed.). Elsevier, London, UK, 55–79 (2011).
  • Schmidt C. GSK/Sirtris compounds dogged by assay artifacts. Nat. Biotechnol.28(3), 185–186 (2010).
  • Quintana A, Müller M, Frausto RF et al. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J. Immunol.183(3), 2079–2088 (2009).
  • Greenlee JE, Clawson SA, Hill KE et al. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J. Neuropathol. Exp. Neurol.69(10), 997–1007 (2010).
  • Gatson NN, Williams JL, Powell ND et al. Induction of pregnancy during established EAE halts progression of CNS autoimmune injury via pregnancy-specific serum factors. J. Neuroimmunol.230(1–2), 105–113 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.